CDMO trends post-Wuxi’s exit from the US: who will take its place?
The Next Frontier Global Leadership on Global Pharma
Insights from Leading Indian CDMOs on the Impact of the BIOSECURE Act and the Shift from Chinese CDMOs
How Indian pharma uses AI to develop faster and cheaper medicines to treat rare diseases
Balancing Innovation with Regulatory Requirements in a CRDMO Setting
Resilient Growth Amidst Funding Fluctuations: How Syngene’s Strategic Vision Outperformed the Market
Syngene Expects Biz to Pick Up by H2 on Funding Revival
Biosecurity threats and business as usual
Three Indian CDMOs ready to seize the BIOSECURE Act opportunity
Indian pharma implements sustainable practices to prevent plastic use & switch to renewable energy sources
